Roche and Chugai Reach Settlement with Biogen Over Actemra Patent Dispute

On October 23 local time, according to a document submitted by Roche to the U.S. District Court for the District of Massachusetts, Roche, Chugai Pharmaceutical, and U.S.-based Biogen Inc. have reached a settlement in the patent lawsuit regarding the alleged infringement by Biogen’s generic drug on Roche's rheumatoid arthritis medication Actemra. Both parties will take steps to withdraw the litigation. Chugai Pharmaceutical stated that the impact on this year's profits would be "insignificant." (Jiemian)Original Link